CA
NZ
UK
AU
IND
US
PepGen is a Boston-based, clinical-stage biotechnology company founded in 2018. Its Enhanced Delivery Oligonucleotide technology uses cell-penetrating peptides to improve the uptake of conjugated oligonucleotide therapies. Its lead candidate, PGN-EDODM1, is being studied in myotonic dystrophy type 1 in the Phase 2 FREEDOM2-DM1 trial.
SeaStar is a Denver-based, commercial-stage medical device company developing extracorporeal therapies built on its Selective Cytopheretic Device platform, which aims to neutralize overactive immune cells in critically ill patients. Its first commercial product received FDA approval in 2024 for pediatric use.
Veradermics is a dermatologist-founded, late-stage biopharmaceutical company based in New Haven, Connecticut. Its lead candidate, VDPHL01, is an oral, non-hormonal extended-release minoxidil tablet in Phase 3 development for pattern hair loss in men and women.
Vivani is an Alameda, California-based, clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants using its NanoPortal technology. Its lead program, NPM-139, is a semaglutide implant designed to deliver six to twelve months of continuous dosing for chronic weight management.
● Full-year non-GAAP EPS guidance raised to $12.80 to $13.00
● TotalDebtcut by $1.1 billion to $15.5 billion during the quarter
● The shorter runway prompted a going-concern flag.
● Management gave a fiscal 2027 revenue outlook of about $648 million to $660 million.
● The company recently communicated clinical updates on its advancing portfolio.
● The company pairs AI-driven surgical planning with patient-specific spinal implants.
Please wait processing your request...